Phase 3 36 items
Trials, agents, guidance
Studies
- Lp(a)FRONTIERS APHERESIS: pelacarsen replaces lipoprotein apheresis in 25 of 26 patients (Parhofer et al., EHJ 2026)Eur Heart J · July 2026 9
- Design and rationale of Lp(a)HORIZON, the first Lp(a) outcomes trial: pelacarsen in 8,323 patients (Cho, Nicholls, Nordestgaard et al., Am Heart J 2025)Am Heart J · September 2025 9
- Alirocumab cuts cardiovascular events regardless of sex, with a larger benefit at higher baseline Lp(a) in women, ODYSSEY OUTCOMES (J Clin Lipidol 2024)J Clin Lipidol · January 2024 9
- Lp(a) reduction from PCSK9 inhibition does not independently lower cardiovascular events, a pooled analysis of 10 phase 3 alirocumab trials in 4983 patients (Atherosclerosis 2019)Atherosclerosis · June 2019 9
- Mass, molar and mass-spectrometry Lp(a) assays predict cardiovascular risk and alirocumab benefit equally in 11,970 ODYSSEY OUTCOMES patients (Circulation 2024)Circulation · August 2023 8
- Pelacarsen cut Lp(a) by 80% in phase 2, letting 98% of patients reach target levels, as the 7,680-patient Lp(a)HORIZON outcomes trial enrolls, a JACC Focus Seminar (J Am Coll Cardiol 2021)J Am Coll Cardiol · March 2021 8
- PCSK9 inhibition lowers LDL cholesterol and Lp(a) discordantly in 20% of patients, a pooled analysis of 4 phase 3 evolocumab trials in 895 patients (J Am Heart Assoc 2019)J Am Heart Assoc · February 2019 8
- Alirocumab sustainably lowers Lp(a) by up to 29% over 1.5 years, a pooled analysis of 10 phase 3 ODYSSEY trials in 4915 patients (Am J Cardiol 2017)Am J Cardiol · September 2016 8
- Mipomersen cuts Lp(a) by 26% across diverse hypercholesterolaemia populations, a pooled analysis of 4 phase 3 trials and 382 patients (Arterioscler Thromb Vasc Biol 2015)Arterioscler Thromb Vasc Biol · January 2015 8
- About 20% of people carry elevated Lp(a), and phase 3 outcome trials of pelacarsen and olpasiran are now testing whether lowering it reduces cardiovascular events (Annu Rev Pharmacol Toxicol 2024)Annu Rev Pharmacol Toxicol · July 2023 7
- Every RNA-based Lp(a) drug tested lowers it by more than 90%, a systematic assessment of 22 trials of pelacarsen, olpasiran, SLN360 and LY3819469 (J Cardiovasc Pharmacol 2023)J Cardiovasc Pharmacol · July 2023 7
- Elevated Lp(a) (>=200 nmol/L) raises cardiovascular event risk by 33% in a cohort mirroring the OCEAN(a)-Outcomes trial population, 3,142 patients (Eur Heart J Open 2023)Eur Heart J Open · July 2023 7
- Trial design challenges for Lp(a)-lowering therapies take center stage as pelacarsen and olpasiran enter phase 3 outcomes trials, a JACC Focus Seminar (J Am Coll Cardiol 2023)J Am Coll Cardiol · April 2023 7
- Pelacarsen lowers Lp(a) by up to 106% in healthy Japanese subjects, supporting the 80 mg monthly dose used in the Lp(a)HORIZON trial (J Clin Lipidol 2023)J Clin Lipidol · December 2022 7
- Alirocumab LDL-C and Lp(a)-lowering effects are discordant in 21.5% of patients, suggesting separate clearance pathways, a pooled analysis of 1,709 patients across 10 ODYSSEY phase 3 trials (Eur J Prev Cardiol 2021)Eur J Prev Cardiol · April 2020 7
- Lepodisiran advances to phase 3 ACCLAIM-Lp(a) outcomes trial, updated review (Cardiol Rev 2026)Cardiol Rev · March 2026 6
- About a quarter of the world has Lp(a) above 50 mg/dL, and gene-silencing drugs dosed a few times a year could finally lower it robustly, a review (Curr Vasc Pharmacol 2024)Curr Vasc Pharmacol · January 2024 6
- Olpasiran and pelacarsen could be cost-effective at AU$1867 and AU$984 per year for secondary prevention of coronary heart disease, an early Australian health technology assessment (J Clin Lipidol 2024)J Clin Lipidol · January 2024 6
- Pelacarsen, olpasiran and SLN360 lower Lp(a) by up to 90%, with pelacarsen phase 3 outcome trial due in 2024, a review (Curr Atheroscler Rep 2022)Curr Atheroscler Rep · September 2022 6
- Over 20% of the population has Lp(a) above 50 mg/dL, and antisense oligonucleotides can cut it by up to 90% as the Lp(a)HORIZON outcomes trial nears results, a review (Curr Atheroscler Rep 2021)Curr Atheroscler Rep · July 2021 6
- Genetics explains 80-90% of Lp(a) variation, up to 1000-fold between people, and antisense drugs can cut it 80% as the HORIZON trial nears, a review (Curr Atheroscler Rep 2021)Curr Atheroscler Rep · June 2021 6
- Antisense drug AKCEA-APO(a)-LRx cuts Lp(a) by up to 80% as a phase 3 outcomes trial is planned, a review of antisense oligonucleotides for Lp(a) (Curr Atheroscler Rep 2019)Curr Atheroscler Rep · May 2019 6
- As Lp(a)-lowering drugs enter outcome trials, should everyone be screened? A review by a leading cardiologist weighs the case (Curr Cardiol Rep 2021)Curr Cardiol Rep · July 2021 5
- Antisense apo(a) inhibitors could pair with statins for patients with both high Lp(a) and high LDL, as phase 3 data approaches, a review (Eur J Intern Med 2020)Eur J Intern Med · April 2020 5
Timeline